新辅助化疗联合保乳术治疗乳腺癌的临床观察

目的探讨对乳腺癌患者实施新辅助化疗后行保乳手术的疗效。方法选取实施新辅助化疗后行保乳手术的20例乳腺癌患者,对其临床资料进行分析。结果 20例患者在实施完化疗后1周,均顺利完成了保乳手术,20例患者术后完全缓解3例,部分缓解15例,稳定2例,无进展病例,客观有效率为90%,且患者全部实现无瘤生存,术后患者对其患侧乳房外形的满意度为95%。20例患者中8例(40%)出现白细胞减少,5例(25%)出现脱发,10例(50%)出现恶心呕吐,通过相关处理后都能较好耐受。结论对乳腺癌患者实施新辅助化疗与保乳术相结合的治疗方法,治疗效果显著,不良反应少,适于临床推广。     

早期乳腺癌保乳术后放射治疗23例临床观察

目的观察早期乳腺癌保乳手术术后放疗的疗效.方法对23例施行保乳手术的早期乳腺癌患者进行放射治疗.结果手术后随访12～48mo,1例同侧乳腺局部复发,复发率4.35%.无远处转移和死亡病例.结论早期乳腺癌实施保乳治疗手术并实行根治性放疗,肿瘤局部控制率满意,提高了患者的生活质量.     

早期乳腺癌保乳手术临床疗效分析

目的:探讨早期乳腺癌保乳手术的临床疗效。方法:选择我院2007年3月~2008年9月早期乳腺癌患者72例,根据自愿加随机的方法分为保乳手术组和改良根治术组,保乳手术组采用象限切除或肿瘤扩大切除术,改良根治术组按常规方法实施。结果:保乳手术组在手术时间、术中出血量、术后引流总量明显小于改良根治术组(P<0.01);保乳手术组局部复发2例、无远处转移及死亡病例,改良根治术组局部复发2例,无远处转移及死亡病例,两组比较差异无统计学意义(P>0.05)。结论:早期乳腺癌保乳手术近期疗效确切,患者满意,是目前早期乳腺癌的又一标准术式,有着良好的前景。     

保乳及根治手术治疗乳腺癌的体力状况评价

目的:观察保乳及根治手术治疗乳腺癌患者的体力状况,并作以比较.方法:对53例乳腺癌手术患者进行手术前后的ZubrodECOG-WHO体力评分,其中21例乳腺癌患者行保乳手术治疗;而另外32例乳腺癌患者行根治手术治疗,并行统计分析.结果:乳腺癌患者经保乳手术及根治手术后,其Zubrod-ECOG-WHO体力评分均有所下降,保乳手术组患者的体力改善的有效率为95.2%,而根治手术的有效率为87.5%,二者差异性明显.结论:保乳及根治手术均能改善乳腺癌患者的体力状况,但保乳手术的体力改善的疗效较根治手术组更显.     

早期乳腺癌保乳手术的临床研究

目的 探讨早期乳腺癌保乳手术的疗效及整形效果。方法从1996年5月到2000年3月为23例早期乳腺癌患者施行保乳手术，术后给予化疗及辅助放疗。本文拟将本组病例与同期早期乳腺癌施行改良根治术50例，做以比较，观察保乳手术是否与根治手术存在疗效上的差异。结果施行保乳手术组与对照组在顸后上没有明显差异，乳房整形效果良好。结论早期乳腺癌保乳手术与改良根治术近期疗效相似，且满足了患者保留乳房的愿望，值得推广。     

早期乳腺癌保乳手术35例临床分析

目的探讨早期乳腺癌保乳手术的适应证、手术方法及临床疗效。方法将72例早期乳腺癌患者随机分为两组，保乳组：35例实施肿块局部扩大切除＋腋窝淋巴结清扫；改良根治组：37例施行改良根治术，两组术后均予以辅助放疗和全身化疗。结果保乳组术后1、3及5a的复发率分别为0％、2．86％、8．57％，生存率分别为100％、97．14％、94．29％；改良根治组术后1、3及5a的复发率分别为0％、2．70％、5．41％，生存率分别为100％、97．30％、94．59％。比较两组病例的术后复发率及生存率，差异无统计学意义（P〉0．05）。保乳组整形效果满意，生活质量良好。结论保乳手术联合辅助放疗和全身化疗治疗早期乳腺癌疗效肯定，美容效果良好，值得临床应用。     

早期乳腺癌行保乳手术治疗分析

目的探讨早期乳腺癌进行保乳手术治疗的疗效。方法2010年5月—2011年5月，我院诊治80例早期乳腺癌患者。均行保乳手术，术后给予相应的放疗和化疗，对其临床疗效进行观察。结果80例早期乳腺癌患者，术中快速病理检查结果均为阴性，实施保乳手术，全部痊愈出院。术后平均随访12个月，未出现任何严重并发症，没有出现肿瘤病灶的远处转移，或者局部复发症状，患者对保乳手术治疗的整体评价较高。结论对于早期乳腺癌患者，严格掌握手术适应证，在确保临床疗效和美观的基础上，应积极实施保乳手术治疗。     

保乳及根治手术治疗乳腺癌的体力状况评价

目的评价保乳及根治手术治疗乳腺癌的体力状况。方法将53例乳腺癌患者随机分为保乳手术治疗组21例与根治手术治疗组32例,保乳手术组患者采用保乳手术治疗,根治手术组采用根治手术治疗,治疗后行体力状况评分。结果保乳手术组的治疗后体力评分为（0333土0130）分,根治手术组（0718±0191）分,两者均较治疗前有所改善,且保乳手术治疗后评分更偏低。结论乳腺癌在严格掌握其手术适应证的前提下,可以大力开展保乳手术来治疗。     

保乳手术治疗乳腺癌效果观察

目的探讨保乳术治疗乳腺癌的治疗方法及疗效。方法对492例乳腺癌患者行保乳术（保乳组）,对同期治疗的590例乳腺癌患者行乳房切除术（对照组）进行对比。结果保乳组在平均手术时间、术中出血量,手术并发症率上均优于对照组。2组复发率及生存率均无统计学意义。结论对乳腺癌病例行保乳术总体疗效比乳房切除术较优。     

保留乳房手术联合放化疗治疗早期乳腺癌

目的观察早期乳腺癌保乳综合治疗的效果。方法 2002年5月—2009年10月,对临床Ⅰ、Ⅱ期乳腺癌患者58例实施了保乳手术。术前检查均明确有手术指征,本着患者自愿选择的原则,采用保乳手术。原发灶做局部广泛切除,术后常规行根治性放疗,于放疗前和放疗后分别评价保乳手术的美容效果。结果共实施保乳手术58例,占同期乳腺癌手术患者的8.2%.肿瘤直径0.5 cm～3.0 cm,术后病理分期0期7例,Ⅰ期34例,Ⅱ期17例。象限切除＋腋窝淋巴结清扫21例,区段切除＋腋窝淋巴结切除28例,单纯区段切除9例。58例患者中,有4例放疗后美容效果不理想。全部病例随访8个月～72个月未发现复发和转移。结论乳腺癌保乳手术美容效果良好,放疗对乳房外形无明显影响,保乳手术加放疗,可显著提高乳腺癌患者的生活质量。     

Breast

<正>209026 Relationship between breast cancer-related lymphoedema and VEGF-C and VGGFR-3/He Jianye (贺建业,DeptGen Surg,Anzhen Hosp,Cap Univ Med Sci, Beijing 100029)…∥Chin J Gen Surg. -2009,24(11). -900～903 Objective To study the distributionand clinicopath-ological characteristics between VEGF-C and peritumoral lymph vessels density (PlND) in breast cancer tissue,and to investigate the development and the mechanism of breast cancer-related lymphoedema(BCRL).     

Breast

<正>210378 Expression and significance of stromal CD10 and Ezrin inductal carcinoma in situ and invasive ductal carcinoma of breast/Zhang Rongju(张荣菊,Breast Cancer Research Key Lab Educat Minis Nation,Oncol Key Lab Tianjin,Tianjin Cancer Inst Cancer Hosp,Tianjin Med Univ,Tianjin 300060)…Chin J Exp Surg.-2010,27(6).-705～707     

Breast

Effect of PTEN on the cell growth and P13K/ AKT signal pathway in Tamoxifen-resistant breast cancer cell-line LCC2;Pacilitaxel in association with gemcitabine for anthracycine-resistant advanced breast cancer;Effect of uroacitides on the cell cycle progression and the expression of Cyclin D1 of breast cancer cells ; Relationship between expression of focal adhesion kinase, tumor suppressor gene PTEN-encoding protein and biological behaviors in breast carcinoma;……     

Breast

Significance of multidisplinary surgery in chest wall resection and reconstruction for selected patients with breast cancer, Relation between c-erbBl,c-erbB2,MAPK expression and resistance to tamoxifen in breast cancer cells in vitro, Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients,Effects of Syk （L） nuclear translocation on breast cancer cell invasion,     

乳腺癌术后的乳房重建

乳房重建能纠正乳房切除术后的形体畸变和减少负面情绪影响,并且不影响乳腺癌的预后及监测。是否进行重建和重建策略的制订需要个体化,必须考虑患者的形体特点、全身情况、乳腺癌治疗计划和个人喜好。乳房重建大体分为假体重建和自体组织重建。假体重建中使用盐水或硅胶假体同样安全有效;自体组织重建通常使用腹部皮瓣,其中腹部游离皮瓣技术能有效保留腹部肌肉,减少术后腹部并发症。无论是假体重建或自体组织重建都有其优缺点,都需考虑后续放疗的影响。     

Breast

<正>209169 Analysis of the treatment and prognosis of recurrent breast phyllodes tumor/Fang Yi(Dept Abdomin Surg,Oncol Cancer Hosp(Institute),Chin Acad Med Sci,Beijing 100021)…∥Chin J Oncol.-2009,31(1).-72~74Objective To explore the methods of diagnosis,treatment and prognosis for patients with recurrent breast phyllodes tumor.Methods Clinicopathological data of 26 patients with pathologically proven recurrent phyllodes tumors treated from March 1972 to June 2006 were retrospectively analyzed.Results The mean age of the 26 cases was 45 years,and the median follow-up duration was 83 months.The mean overall survival time of this series was 96 months.The primary breast phyllodes tumor was ≥5 cm in 10 cases with a recurrence rate of 60.0%(6/10 cases);<5 cm in 16 cases with a recurrence rate of 31.3% 5/16(cases).After surgical removal of the breast primary tumor,the recurrent tumor was ≥5 cm in 14 cases with a re-recurrence rate of 35.7%(5/14 cases);<5 cm was in 12 cases with a re-recurrence rate of 50.0% (6/12 cases).There was no statistically significant relationship between the(primary and reccurent)tumor size and recurrence rate(P=0.094,P=0.383)or prognosis,(P=0.142,P=0.486).The benign or malignant nature of the breast phyllodes tumor was singificantly correlated with the rate of local re-recurrence(P=0.046)and prognosis(P=0.028).     

Breast

Technique investigation of endoscopic axillary lymph node dissection by liposuction , The study on sentinel lymphatic channels by us. ing methylene blue in breast cancer patients , A study of the combination of vinorelbine and epirubicin as ncoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer , Epidermal growth factor receptor signaling pathway in tamoxifen-resistant breast cancer cells     

Breast

A retrospective study of 129 cases with immediate breast reconstruction after skin-sparing mastectomy for breast cancer; Expression of imprinted tmnor suppressor gene SLC22A18 in breast cancer; WWOX gene expression and aberrant CpG island hypermethylation of WWOX gene in breast cancer; Are there other axillary lymph node metastasis than positive sentinel lymph nodes containing micrometasrases and isolated tumor cells in patients with breast cancer.     

Breast

<正>209325 Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes/Zhang Huiming(张慧明,Dept Abdom Surg Oncol,Cancer Hosp(Inst),Chin Acad Med Sci Peking Union Med Col,Beijing 100021)…∥Chin J Oncol.-2009,31(6).-447～451Objective According to the immunohistochemical (IHC)test of ER,PR and HER-2,breast cancer can be divided into 4 different molecular subtypes:Luminal A subtype (ER or PR positive and HER-2 negative),Luminal B subtype (ER or PR positive and HER-2 positive),HER-2 sutype (ER and PR negative,HER-2 positive) and Basal-like subtype (ER,PR and HER-2 negative).This study was to analyze the clinical features of different breast cancer subtypes,and try to find the evidence of combined and individualized treatment for patients with breast cancer.Methods The data of 408 surgically treated breast cancer patients in the Cancer Hospital of Chinese Academy of Medical Sciences from January 1,2002 to December 31,2002 were collected and retrospectively analyzed.The clinicopathological features and recurrence,metastasis as well as survival of these four subtypes were compared.Results Of the 408 cases,Luminal A subtype accounted for 60.8% (248/408),Luminal Bsubtype 7.8% (32/408),HER-2 subtype 12.5%(51/408),and Basal-like subtype 18.9%(77/408).Basal-like subtype had less lymph mode metastases than other subtypes(P<0.05).HER-2 subtypes consisted of less patients aged 45 years or younger than other subtypes(P<0.05).Luminal B subtype contained less advanced cases than other subtypes(P<0.01).By August 2008,the median time of follow-up was 64 months (range,3-79 months).Fifty-eight cases presented local recurrence or metastasis,and 51 of them died of the disease.The 5-year overall survival rates (OS) for patients with Luminal A,Luminal B,Basal-like and HER-2 subtype were 89.83%,86.15%,79.85% and 86.70%,respectively.The 5-year disease-free survival (DFS) rates of the four subtypes were 83.52%,68.88% and 75.83%,respectively.The rate of local recur